Methylmalonic acidemia (MMA), an inherited metabolic disorder caused by deficient activity of methylmalonyl-CoA mutase, carries a poor prognosis for long-term survival. While administration of a recombinant adeno-associated virus serotype 8 vector (rAAV8) can rescue Mut À/À mice from neonatal lethality and provide sustained phenotypic correction, translation of gene therapy to human subjects will likely require multiple rounds of systemic administration and, ideally, the use of a vector that transduces the kidney. To examine the effectiveness of alternative rAAVs in the treatment of MMA, a serotype 9 rAAV expressing the Mut cDNA was constructed and delivered to newborn Mut À/À mice (n¼11). rAAV9 gene therapy directed hepatic transgene expression within 24 h and effectively rescued the Mut À/À mice from lethality, conferred long-term survival, markedly improved metabolism and resulted in striking preservation of renal function and histology. Systemic readministration of the vector at a dose similar to that used in human clinical trials (2.5Â10 9 GC of rAAV9 per gram) to older, treated Mut À/À mice (n¼5) lowered circulating metabolites, increased in vivo propionate oxidative capacity and produced transgene expression in the kidney and liver. Our data support the use of an rAAV9 vector in the acute and chronic treatment of MMA, and highlight the renal tropism afforded by this novel serotype.
INTRODUCTION
Methylmalonic acidemia (MMA) is an autosomal recessive inborn error of organic acid metabolism characterized by severe metabolic instability, multiorgan pathology and a poor prognosis for long-term survival. [1] [2] [3] [4] [5] [6] [7] This disorder is most commonly caused by deficient activity of methylmalonyl-CoA mutase, 1 the 5¢-deoxyadenosylcobalamin-dependent enzyme that isomerizes L-methylmalonyl-CoA into succinyl-CoA in the mitochondrial inner space.
Current management approaches for vitamin B12 (hydroxocobalamin) non-responsive MMA patients include dietary restriction of propiogenic amino acids, nutritional supplement administration and vigilant monitoring. Liver or combined liver/kidney transplantation have been used to treat those with the most severe clinical manifestations. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Patients with MMA, even those who have received liver transplants, can develop progressive renal dysfunction, 11 pathologically characterized by tubulointerstitial nephritis, 18, 19 and eventually require kidney transplantation. 20 Whether circulating metabolite(s) and/or a cell intrinsic defect underlies the renal pathology of MMA remains unknown. 21 The disease manifestations seen in the patient population, even those who have been intensively treated, demonstrate the need for new therapies, ideally ones that could target both the liver and kidney, to increase stability and protect from renal insufficiency.
We have previously demonstrated that a recombinant adenoassociated virus serotype 8 (rAAV8) vector expressing the murine Mut gene under the control of the cytomegalovirus enhancer/chicken b-actin promoter could rescue newborn Mut À/À mice from neonatal lethality and provide long-term phenotypic correction. 22 Although neonatal rAAV8 gene therapy effectively targeted numerous tissues in Mut À/À mice, particularly the liver and skeletal muscle, transgene expression was not detectable in the kidney and decreased in other tissues over time. This suggests that translation to human subjects would likely require multiple rounds of gene delivery throughout life. Alternative rAAV vectors that could provide enhanced renal tropism with the potential to be administered in the setting of an immune response to rAAV8 may be required for effective gene therapy application in humans.
AAV serotypes are numerous, exhibit distinct tissue tropism and offer the potential for optimization of gene delivery to specific target tissues and/or cell types. 23, 24 Among the naturally occurring adenoassociated viruses isolated from simian and human tissues, serotype 9 has recently been recognized as superior in the ability to direct hepatic and renal gene transfer in a mouse model of renal tubulointerstitial fibrosis. 25 These properties, coupled with previous studies showing that rAAV9 vectors exhibit rapid and widespread transgene expression in mice and larger animals, [26] [27] [28] suggest that a serotype 9 rAAV vector would be promising in gene therapy applications for MMA. [25] [26] [27] [28] [29] [30] [31] To explore the use of this novel serotype in the treatment of mice with MMA, we developed and characterized an AAV serotype 9 vector, rAAV9-CBA-mMut, to express Mut from the enhanced, chicken b-actin promoter. 32 Intrahepatic delivery of rAAV9-CBA-mMut effectively rescued Mut À/À mice from neonatal lethality, provided immediate and persistent expression of the transgene, and after low-dose systemic reinjection at 1 year, directed expression of the transgene in the liver and kidney. These studies highlight the novel characteristics of rAAV9-mediated gene delivery as a treatment for MMA, particularly rapid transgene expression in vivo and tropism for the kidney, an organ involved in the pathophysiology of many hereditary and acquired disorders.
RESULTS
Gene therapy with low-dose AAV9 rescues the lethal Mut À/À phenotype Mut À/À mice received a single dose of 1Â10 10 vector genome copies of rAAV9-CBA-mMut by intrahepatic injection at birth (n¼11). While two treated Mut À/À mice died within the first 48 h, 82% of the mice that received rAAV9-CBA-mMut gene therapy survived 1 year post treatment ( Figure 1) . All of the untreated Mut À/À mice died by day of life 72, with more than 90% mortality occurring by day of life 24 ( Figure 1 ). In contrast, at 1 year, 89% of the injected heterozygous control littermates were alive. Deceased mice were autolysed, cannibalized or entirely missing from their cages. rAAV9 gene therapy vector leads to rapid and high-level expression of the mutase transgene To examine the expression kinetics of the viral transgene in the immediate pre-injection period, livers from treated newborn Mut À/À mice were collected at 24 and 72 h after treatment with either 1Â10 10 GC of rAAV9-CBA-mMut or rAAV2-CBA-mMut, a serotype that has well-studied uncoating properties in the murine liver. 33 Untreated Mut +/À and Mut À/À littermate livers were harvested in parallel and served as controls. There was no detectable level of immunoreactive mutase enzyme in untreated Mut À/À mice ( Figure 2 ). However, as early as 24 h after injection, rAAV9-CBA-mMut-treated Mut À/À mice demonstrated hepatic Mut protein at levels similar to those seen in untreated Mut +/À animals ( Figure 2) . By 72 h, Mut expression continued to increase in the rAAV9-CBA-mMut-treated Mut À/À mice ( Figure 2 ). In contrast, Mut was absent in Mut À/À mice similarly treated with rAAV2-CBA-mMut ( Figure 2 ) at both times, demonstrating the influence of the serotype and tropism on early transgene expression in the liver.
Growth improvement after gene therapy
Although untreated Mut À/À and Mut +/À mice are indistinguishable at birth, the rare Mut À/À animals that survive neonatal lethality present signs of severe growth retardation. 34 By 2 months of age, untreated Mut À/À mice weigh less than one third as much as sex-matched Mut +/À littermates, appear grossly abnormal and uniformly perish by 72 days. 22 In contrast, Mut À/À mice treated with rAAV9-CBA-mMut were significantly larger than untreated Mut À/À mice (Figure 3a ; ***Po0.001). They appeared and behaved in an identical manner as treated control littermates, but were slightly smaller than heterozygous littermates, even after vector readministration (Supplementary Figure 1) . Furthermore, treated Mut À/À mice thrive on a regular diet, unlike untreated Mut À/À mice that have to be maintained on a high-fat and carbohydrate diet.
Restoration of Mut function and activity
In order to study the efficacy of gene therapy, we analyzed various parameters that reflect the Mut enzymatic activity and function, including metabolite concentrations and ability of the treated Mut À/À mice to oxidize 1-13 C-sodium propionate into 13 CO 2 . Compared with controls, plasma MMA levels remained significantly elevated at all times in the treated Mut À/À mice, and stabilized at 323 mmol l À1 ( ± 30 mmol l À1 ) by 1 year of life (Figure 3b) .
Mice with functional hepatic Mut activity can oxidize 1-13 C-sodium propionate into 13 CO 2 . 22 This activity is markedly reduced in untreated Mut À/À mice (Figure 3c ). At 9 months, rAAV9-CBAmMut-treated Mut À/À mice and heterozygous littermates were injected with 1-13 C-sodium propionate and breath samples were collected while the CO 2 production rate was measured. Mut +/À mice convert B50% of 1-13 C-sodium propionate into 13 CO 2 in 25 min (n¼3) whereas untreated Mut À/À mice (n¼6) oxidize only B10% of the injected dose (Figure 3c ). At 9 months post treatment, 1-13 C-propionate oxidation was significantly increased above the untreated state in the rAAV9-CBA-mMut-treated Mut À/À mice (n¼5; Figure 3c ), demonstrating that the Mut transgene was persistently expressed and functional in vivo.
rAAV9 gene therapy preserves the glomerular filtration rate and kidney cytoarchitecture Because human MMA patients suffer from kidney failure and previous studies have established that older, untreated Mut À/À mice exhibit severe and widespread tubulointerstitial changes, 34 we examined the effect of gene therapy on kidney function and histology in the rAAV9-CBA-mMut-treated Mut À/À mice. The measured glomerular filtration rate (GFR) did not significantly differ between the rAAV9-CBAmMut-treated Mut À/À (n¼3) and Mut +/À mice (n¼3; Figure 3d ). As the untreated Mut À/À littermates perish, GFR measurements values for untreated, matched mutant controls are not available for comparison. Kidney histology was next examined in rAAV9-CBA-mMut-treated Mut À/À mice (n¼6) and compared with Mut +/À littermates (n¼3). Consistent with the GFR measurements, renal histology in the rAAV9-CBA-mMut-treated Mut À/À mice was unremarkable, without characteristic tubulointerstitial changes, and appeared identical to the rAAV9-CBA-mMut-treated Mut +/À control mice (Supplementary Figure 2) .
Low-dose systemic reinjection of rAAV9-CBA-mMut at 1 year results in metabolic improvements and transgene expression in the kidney One year after neonatal injection, a set of treated rAAV9-CBA-mMut Mut À/À mice (n¼5) were reinjected with a low dose of rAAV9-CBAmMut (2.5Â10 9 GC gram À1 ) delivered by the retro-orbital route.
Measurement of the concentration of methylmalonic acid in the plasma, and whole-body 1-13 C-sodium propionate oxidative capacity monitored the metabolic effects of reinjection. Within 3 days after readministration of rAAV9-CBA-mMut, the plasma methylmalonic acid concentrations significantly decreased to 126 mM (±11 mM; Po0.001) compared with pretreatment levels of 323 mM ( ± 30 mM; Figure 4a ), and 1-13 C-sodium propionate oxidative capacity increased (Figure 4b ). The extent of metabolic improvement remained stable 1 month after reinjection, the plasma methylmalonic acid was unchanged ( Figure 4a ) and 1-13 C-sodium propionate oxidation was equivalent between the reinjected rAAV9-CBA-mMut Mut À/À mice (n¼5) and heterozygote controls (n¼3; Figure 4b ).
Expression of Mut after reinjection with rAAV9-CBA-mMut
A set of rAAV9-CBA-mMut Mut À/À mice (n¼2) were killed 1 month after reinjection to examine transgene expression compared with a rAAV9-CBA-mMut Mut À/À mouse injected at birth and killed at 1 year of age. After 1 year, the level of immunoreactive Mut in the liver of a rAAV9-CBA-mMut-treated Mut À/À mouse was similar to that seen in an untreated Mut +/À control (Figure 4c) , and showed persistent expression at 1 and 2 months after reinjection with rAAV9-CBA-mMut (Figure 4c ). Mut was not present in a kidney extract prepared from a Mut À/À mouse that was treated only with a single neonatal injection of rAAV9-CBA-mMut, but was readily detected 1 month after systemic reinjection (Figure 4d ). Further analysis using quantitative PCR confirmed that Mut mRNA was present in the kidney of the re-treated rAAV9-CBA-mMut Mut À/À mice, but at levels well below those measured in heterozygous littermates (data not shown). Western analysis using liver and kidney extracts from reinjected rAAV9-CBA-mMut Mut À/À mice were also examined 2 months after reinjection and yielded similar results to those seen at the earlier 1 month time point. This supports the observation that there is Mut expression in the kidney following systemic gene therapy with rAAV9-CBA-mMut (Figure 4d ).
DISCUSSION
In this study, we demonstrate the efficacy of an rAAV9 vector to treat MMA in a mouse model that replicates the features of severe human disease. Consistent with reports showing that serotype 9 AAV vectors are highly efficacious gene delivery agents in mice, 26 we have achieved long-term correction of the neonatal lethal phenotype seen in the untreated Mut À/À mice using a 10-fold lower dose than that previously used with rAAV8 vectors. 22, 35 Early and long-term transgene expression, proven by expression of Mut gene in the liver of Mut À/À mice as early as 24 h post treatment with persistence to 1 year and beyond, likely contributes to the biological efficacy of this gene therapy approach. The rescued Mut À/À mice were vigorous and appeared well, tolerated a non-restricted diet and had markedly improved metabolic parameters compared with the untreated state. Like patients who receive liver and combined liver/kidney transplants, 8 the circulating metabolites were not normalized in the treated mice. However, the clinical effects of rAAV9-CBA-mMut gene therapy endured throughout life, as the animals appeared and acted in a manner identical to control littermates. Recently, the potential of rAAV9 to transduce the kidney and provide biological efficacy in a genetic mouse model of tubulointerstitial renal disease has been established. 25 As kidney failure is a wellrecognized and devastating complication of MMA, we also examined fluorescein isothiocyanate (FITC)-inulin clearance in the treated Mut /À mice to measure the GFR, a sensitive measure of renal function. No significant differences were observed between Mut +/À and rAAV9-CBA-mMut-treated Mut À/À mice in our GFR study. Although the manifestations of renal disease in mouse models of MMA are not fully explored, previous studies have established that tubulointerstitial nephritis, similar to what has been documented in MMA patients, does occur in older, untreated Mut À/À mice that escape lethality. 34 In the small number of rAAV9-treated Mut À/À mice that were killed after GFR studies were performed at 1 year of age, renal histology was similar to that seen in treated controls and showed no tubulointerstitial changes (Figure 3d and Supplementary Figure 2) . That the treated Mut À/À mice studied here tolerated a non-restricted diet, have normal glomerular kidney function and have no evidence of tubulointerstitial changes suggest that rAAV9 gene therapy has ameliorated the progression of MMA-associated kidney damage, either by transduction of a critical renal cellular element, such as the proximal tubule, or by reducing the 'nephrotoxic' metabolite load.
In light of the published data showing that rAAV9 can be readministered and still mediate high levels of transgene expression, even in the presence of neutralizing antibodies, 36 a subset of treated Mut À/À mice were reinjected at 1 year of age. A dose of rAAV9-CBAmMut similar to that used in human clinical trials with other rAAVs (2.5Â10 9 GC gram À1 ) 37 was systemically delivered. As early as 3 days post injection, the reinjected Mut À/À mice exhibited improved metabolism and the response persisted for at least 1 month post treatment, despite the fact that the circulating metabolites remained substantially increased in re-treated Mut À/À mice. These findings demonstrate that a second round of gene delivery can substantially replenish Mut enzymatic activity in vivo and can be readily measured using a combination of circulating and whole-body metabolic parameters.
In order to determine whether a systemic rAAV9-CBA-mMut readministration resulted in a greater transgene expression in the liver and kidney, tissues were harvested 1 or 2 months after reinjection, analyzed by western blotting and quantitative PCR, and the results were compared with that of mice that had received only a single rAAV9-CBA-mMut treatment at birth. Mut À/À mice that received only a single injection at birth had hepatic Mut protein levels comparable to treated heterozygous littermates. In Mut À/À mice that received a second injection of rAAV9-CBA-mMut at 1 year, transgene expression further increased in the liver (Figure 4c ). Although one otherwise asymptomatic treated Mut À/À mouse had elevated LFTs before vector readministration (Supplementary Figure 3) for an unknown reason, liver function tests in the multiply treated animals did not reveal AAV9-associated transaminitis. As rAAV9 has been reported to transduce the kidney in mice, 25, 26 we next examined whole-kidney extracts prepared from mice at 1 month and 2 months after systemic reinjection. Immunoreactive enzyme was apparent in the Mut À/À kidneys studied after re-treatment, compared with undetectable levels present before reinjection. These data establish that a second injection of rAAV9-CBA-mMut, systemically delivered at a dose equal to that used in human trials for other AAV serotypes, resulted in significantly increased Mut expression in both the liver and the kidney.
The studies presented here clearly demonstrate the therapeutic potential of a serotype 9 rAAV vector to effectively deliver the Mut gene in a mouse model of MMA that faithfully replicates the severe human phenotype. The rapid hepatic transgene expression we have documented in rAAV9-CBA-mMut-treated neonatal Mut À/À mice suggests that a rapidly uncoating rAAV vector 33 might be used to treat MMA patients acutely in the setting of metabolic decompensation, perhaps as early as the newborn period. Transduction of the liver, and especially the kidney, further supports the consideration of AAV serotype 9 gene therapy vectors for future use in the treatment of patients with MMA.
MATERIALS AND METHODS

Murine model of MMA
Mut À/À mice contain a deletion of exon 3 in the methylmalonyl-CoA mutase gene, display neonatal lethality and exhibit massive elevations of methylmalonic acid in the blood, urine and tissues. 38 Mut RNA, protein and enzymatic activity are undetectable in Mut À/À mice. Mut +/À mice have biochemical parameters identical to Mut +/+ mice and were used as controls throughout the study. 22, 38 rAAV9 construction, production and delivery
The murine Mut cDNA was cloned into the pAAV2-CI-CB7-RBG expression plasmid to generate rAAV9-CBA-mMut. pAAV2-CI-CB7-RBG contains the transcriptional control elements from the cytomegalovirus enhancer/chicken b-actin promoter, cloning sites for the insertion of a complementary DNA and the rabbit b-globin polyA signal flanked by AAV2 terminal repeats. 32 rAAVs were subsequently packaged with either AAV9 or AAV2 capsid, purified by cesium chloride centrifugation or column chromatography, and titered by quantitative PCR as previously described. 39 rAAV9-CBA-mMut had a titer of 1.38Â10 12 GC ml À1 ; rAAV2-CBA-mMut had a titer of 5.52Â10 12 GC ml À1 . In all, 1Â10 10 GC of the viral vector was delivered to neonatal mice via intrahepatic injection immediately after birth. 22 At 1 year of age, a subset of mice that had been injected in the neonatal period were re-treated with 2.5Â10 9 GC per gram body weight rAAV9-CBA-mMut delivered via retro-orbital injection. The National Human Genome Research Institute Animal User Committee approved all animal studies.
Western blotting
Tissue samples were homogenized in T-PER tissue protein extraction buffer (Pierce Biotechnology, Rockford, IL, USA) in the presence of Halt protease inhibitor cocktail (Pierce Biotechnology) using a 2-ml Tenbroeck tissue grinder (Wheaton, Millville, NJ, USA). Protein extracts were analyzed by western blot and probed with rabbit polyclonal antibodies against the Mut enzyme. 22 Mitochondrial loading control was detected with mouse monoclonal antibodies against complex III core II (SKU# A-11143, Invitrogen, Carlsbad, CA, USA). The anti-Mut antibodies were used at a dilution of 1:1000 and the antiComplex III Core II antibody was used at a dilution of 1:3000. Horseradish peroxidase-conjugated anti-rabbit IgG (NA934; GE Healthcare Life Sciences, Piscataway, NJ, USA) or anti-mouse IgG (NA931; GE Healthcare Life Sciences) were used as secondary antibodies and visualized after chemiluminescence detection (Pierce Biotechnology).
Metabolic studies
Blood samples were collected from treated mice by orbital bleeding. Plasma was isolated by centrifugation, diluted in water and stored at À801C in a screw-top tube. Methylmalonic acid concentrations in plasma were measured by gas chromatography-mass spectrometry. 40, 41 To determine 1-13 C-propionate oxidation in vivo, mice were placed into a respiratory chamber after intraperitoneal injection of 200 mg of 1-13 C-sodium propionate. 22, 42 Breath samples from mutant, control and treated mice were collected at 5, 15 and 25 min after injection and the isotope ratio ( 13 C/ 12 C) of the expired gas was measured with a gas isotope ratio mass spectrometer (Metabolic Solutions, Nashua, NH, USA). The percent dose oxidized at each time point was calculated as:
% dose oxidized ¼ total 13 C excreted ðmmol=doseðmmolÞÂ100%Þ
Glomerular filtration rate
The GFR was measured using the FITC-labeled inulin clearance method. 43 Experiments were performed on age-and sex-matched Mut +/À (n¼3) and Mut À/À mice (n¼3) at 1 year of age. All of the mice had received a single neonatal intrahepatic injection of rAAV9-CBA-mMut. Under isoflurane anesthesia, mice were given a single retro-orbital bolus injection of 5% FITC-labeled inulin (3.74 ml per gram body weight). Heparinized serial blood collections were performed from tail cuts at 3, 7, 10, 15, 35, 55 and 75 min after inulin administration and the plasma was subsequently removed. As pH affects FITC fluorescence values, each plasma sample was buffered by mixing 1 ml plasma with 9 ml of 500 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid solution (pH 7.4). The amount of FITC label present in the samples was then measured using a fluorospectrometer at 538 nm emission (NanoDrop 3300, Thermo Scientific, Wilmington, DE, USA). A two-compartment clearance model was used to calculate the GFR. Plasma fluorescence data were fit to a two-phase exponential decay curve using nonlinear regression (GraphPad Prism, GraphPad Software, San Diego, CA, USA). GFR (ml min À1 ) was calculated using the equation: GFR¼I/(A/a+B/b). I is the amount of FITC-inulin delivered by injection, A and B are the y-intercept values of the two decay rates, and a and b are the decay constants for the distribution and elimination phases, respectively.
Statistical analyses
Differences in the survival between treated and untreated groups were analyzed using a w 2 -test. Differences in weight, metabolite levels and GFRs were assessed using a Student's t-test. The Kruskal-Wallis test was used to determine the statistical significance in measured propionate oxidation rates between groups at 25 min after injection. P-values o0.05 were considered significant.
